198
Participants
Start Date
November 30, 2014
Primary Completion Date
December 14, 2017
Study Completion Date
December 22, 2020
Viaskin Milk 150 mcg
Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 150 mcg cow's milk proteins.
Viaskin Milk 300 mcg
Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 300 mcg cow's milk proteins.
Viaskin Milk 500 mcg
Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 500 mcg cow's milk proteins.
Viaskin Placebo
Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing a matching placebo formulation.
Mount Sinai Medical Center, New York
Children's Hospital of Pittsburgh, Pittsburgh
Children's Hospital of Philadelphia, Philadelphia
Johns Hopkins Hospital, Baltimore
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Arkansas Children's Hospital, Little Rock
Children's Medical Center of Dallas, Dallas
Children's Hospital Colorado, Aurora
Rady Children's Hospital, San Diego
Stanford University School of Medicine, Stanford
ASTHMA, Inc., Seattle
Massachusetts General Hospital, Boston
Cheema Research Inc., Mississauga
Ottawa Allergy Research Corporation, Ottawa
Gordon Sussman Clinical Research Inc., Toronto
Centre Hospitalier Universitaire Sainte Justine, Montreal
Clinique Spécialisée en allergie de la Capitale, Québec
Lead Sponsor
DBV Technologies
INDUSTRY